pharmaphorum

OCTOBER 2, 2020

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects.

Clinical Trials 92

Clinical Trials Clinical Trials Clinical Research Life Science 92

Velocity Clinical Research

DECEMBER 6, 2023

In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. As a result, Sponsors and CROs can benefit from simplified access to international clinical research capabilities. and Europe.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

pharmaphorum

JUNE 17, 2022

The UK-based but US-listed biotech licensed rights to AZ’s orally-active neutrophil elastase inhibitor alvelestat for the rare disease alpha-1 antitrypsin deficiency (AATD) five years ago, and has since advanced the project into a phase 2 trial which is due to read out in the second half of this year.

Licensing 81

Licensing Licensing Cardiology Antibody 81

pharmaphorum

JUNE 25, 2021

But Dr Craig Granowitz, chief scientific officer of cardiology drug developer Amarin, says that this is only the tip of the iceberg when it comes to the devastating impact of CVD on global populations. “In But one of the biggest issues in changing people’s expectations and improving outcomes is “apathy”, he says. Think about that.

Cardiology 100

Cardiology Drugs Development Clinical Trials 100

Velocity Clinical Research

NOVEMBER 21, 2023

“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

ACRP blog

JANUARY 24, 2023

This expanded clinical research opportunities for patients as a core pillar of the affiliation’s mission, with the goal of providing access to novel treatments for diagnoses in addition to standard of care. An important step was a review of the state of clinical trial awareness at the time of the affiliation agreement.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Velocity Clinical Research

MARCH 7, 2024

It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA , Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council , discusses their importance to patients yesterday, today, and tomorrow.

Doctors 52

Doctors Doctor Clinical Research Clinical Trials 52

XTalks

JUNE 26, 2023

According to Surmodics, SurVeil DCB is approved to be marketed and sold in the US for percutaneous transluminal angioplasty of de novo or restenotic lesions in femoral and popliteal arteries having reference vessel diameters of 4 mm to 7 mm. SurVeil has an edge over IN.PACT as it is coated with a lower dose of the drug.

FDA Approval 96

FDA Approval Drugs Sales In-Vitro 96

pharmaphorum

JANUARY 5, 2021

An IQVIA survey to Neurology, Cardiology, Rheumatology, Dermatology and Ophthalmologists in June 2020 across the lead five European countries showed an average of 30% of patients either “no shows” or still waiting for treatment that was delayed. The post pandemic launch. Even if they do, however, their savings will be lower.

Sales 105

Sales Marketing Production Vaccination 105

Delveinsight

AUGUST 3, 2021

DelveInsight’s analysis in the report titled, DelveInsight’s Chronic Pain associated with Painful Diabetic Neuropathy – Epidemiology Forecast – 2030 Market Insights, Competitive Landscape and, Market Forecast – 2026 , the market size of the Senza Omnia system is estimated to increase to around USD 3,500 million by 2026.

FDA Approval 98

FDA Approval Marketing Cardiology Production 98

The Pharma Data

JUNE 28, 2021

Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. Food and Drug Administration (FDA) in January 2021 and was recommended for marketing authorization by the Committee for Medicinal Products for Human Use (CHMP) in the EU in May 2021. Kenilworth, NJ, USA).

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

XTalks

AUGUST 22, 2022

The Toronto-based company has recently announced positive results from an independent clinical trial which showed that their fluorescence imaging device MolecuLight i :X improved 12-week wound healing of diabetic foot ulcers by 204 percent. The challenge is that other specialities have diagnostic imaging to assist clinicians.

Bacteria 111

Bacteria Containment Sales Cardiology 111

pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Life Science 52

pharmaphorum

MAY 18, 2021

billion acquisition of Corvidia Therapeutics in June last year, The deal saw the firm begin to explore new markets after making its name in diabetes, a market which is being squeezed by pricing pressures. Data were announced at the virtual American College of Cardiology annual conference and published simultaneously in The Lancet.

Drugs 52

Drugs Cardiology Trials Clinical Trials 52

Delveinsight

JULY 22, 2021

The decision gave Bayer complete control of BlueRock’s cell therapy pipeline, headed by DA01 and spanning various diseases in the neurology , cardiology , and immunology categories. To do so, Omniscient will utilize the financing to expand market access for its existing brain-mapping platforms, in part by increasing its global sales team.

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

The Pharma Data

FEBRUARY 21, 2022

Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.

Radiology 52

Radiology Cardiology Development Production 52

The Pharma Data

OCTOBER 14, 2020

“The global heart failure market represents a tremendous opportunity for Sequana Medical and we look forward to providing an update on the interim results from our RED DESERT study later this year.”. market for the alfa pump resulting from NASH-related cirrhosis is forecast to exceed €3 billion annually within the next 10-20 years.

Cardiology 40

Cardiology Clinical Trials Clinical Trials Medicine 40

Cloudbyz

AUGUST 16, 2024

Introduction to Electronic Case Report Forms (eCRF) In the ever-evolving landscape of clinical trials, the transition from traditional paper-based case report forms to electronic Case Report Forms (eCRFs) has marked a significant advancement in how clinical data is collected, managed, and analyzed.

Clinical Trials 52

Clinical Trials Clinical Trials Compliance Trials 52

The Pharma Data

SEPTEMBER 27, 2021

This follows results from the phase III clinical trial EMPEROR-Preserved trial which investigated the composite endpoint of cardiovascular death or hospitalization for coronary failure in patients with HFpEF.1. Empagliflozin is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes.6,7,8

Clinical Trials 52

Clinical Trials Clinical Trials Trials Cardiology 52

The Pharma Data

JANUARY 20, 2021

Teerlink is actively involved in many acute and chronic heart failure clinical trials, serving on endpoint, data safety monitoring, and steering committees for numerous international cardiovascular studies. Cardiol recently commercialized Cortalex ( cortalex.com ) in the Canadian market. alone exceeding $30 billion.

Trials 52

Trials Cardiology Containment Development 52

The Pharma Data

NOVEMBER 16, 2020

The “polypill” containing three generic blood pressure medications and a statin dramatically reduced the risk of heart-related illness in people with no prior history of heart problems, according to clinical trial results. A single pill also is cheaper to market and distribute. ” Yusuf said. .

Doctor 52

Doctor Doctors Cardiology Medicine 52

The Pharma Data

JULY 12, 2021

“The Phase III FIDELIO-DKD trial is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes. FDA has approved finerenone for marketing authorization in the U.S.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

The Pharma Data

SEPTEMBER 11, 2021

This follows results from the Phase III EMPEROR-Preserved trial which investigated the composite endpoint of cardiovascular death or hospitalization for heart failure in patients with HFpEF. Empagliflozin is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes. About empagliflozin.

Trials 52

Trials Clinical Trials Clinical Trials Medicine 52

XTalks

FEBRUARY 9, 2024

As we delve into the top 15 cardiovascular disease drugs in 2023, guided by comprehensive 2022 sales data, we gain valuable insights into the market trends, drug efficacy and the evolving needs of patients worldwide. Eliquis’ growing success in recent years owes largely to gains in the non-valvular atrial fibrillation market.

Sales 59

Sales FDA Approval Drugs Marketing 59

The Pharma Data

NOVEMBER 4, 2020

Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. This press release and further information about Alexion can be found at: www.alexion.com.

Antibody 52

Antibody Containment Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 30, 2021

The European, Israeli and East Asian results were presented at the 81 st American Diabetes Association (ADA) Scientific Sessions, with further European analyses to be revealed at the European Society of Cardiology (ESC) Heart Failure Congress in June–July 2021, and the ESC Congress in August 2021. Source link: [link].

Trials 52

Trials Clinical Trials Clinical Trials Medicine 52

The Pharma Data

NOVEMBER 2, 2020

market and congratulate all Chiesi team members and partners who supported the clinical process.”. In three large-scale global clinical trials totaling 761 patients aged 18 years and older, Bronchitol use led to a sustained improvement in FEV 1 (Forced Expiratory Volume) versus control. in March, 2021.

FDA Approval 52

FDA Approval Bacteria Medicine Cardiology 52

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

Medicine 52

Medicine RNA Production Marketing 52

Pharma Marketing Network

JANUARY 12, 2023

During the course of her more than 30 years in the industry, she has spanned a broad range of therapeutic areas, including oncology, immunology, infectious disease, cardiology, neuroscience, Alzheimer’s disease, medical devices, and more.

Life Science 52

Life Science Manufacturing Cardiology Development 52

The Pharma Data

AUGUST 30, 2021

Professor of Cardiology at the National and Kapodistrian University of Athens, Greece, and co-principal investigator of the FIDELIO-DKD and FIGARO-DKD Phase III clinical trials. In July, finerenone was approved under the brand name Kerendia ® by the United States (U.S.) About Finerenone.

HR 52

HR Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 30, 2021

Results from the Phase III EMPEROR-Preserved trial were presented today at the European Society of Cardiology Congress 2021 2 and published in The New England Journal of Medicine 1. Cardio-renal-metabolic conditions are the leading cause of mortality worldwide and account for up to 20 million deaths annually. About empagliflozin.

Trials 52

Trials Cardiology Medicine Clinical Trials 52

XTalks

JULY 10, 2023

We did not get a Class II certification for diabetes only, or orthopedics or cardiology; we got a disease-agnostic certification. Now, as we develop new predictive algorithms, whether that is in diabetes, cardiology, respiratory or oncology, we can bring those algorithms to our platform because it is disease-agnostic.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

XTalks

FEBRUARY 8, 2024

Understanding the market dynamics of diabetes treatments becomes crucial for professionals across these industries. Both drugs continue to dominate the diabetes and GLP-1 markets. It’s been widely marketed and is considered a leading medication in the SGLT2 inhibitor class. percent in the fourth quarter and decreased 56.7

Sales 52

Sales Insulin FDA Approval Drugs 52

The Pharma Data

AUGUST 30, 2021

Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). In three clinical trials, patients taking Leqvio maintained LDL-C reduction throughout each six-month dosing interval 8,10. In the first analysis, patients with established CeVD treated with Leqvio achieved an average 55.2%

RNA 52

RNA Trials Production Containment 52

The Pharma Data

APRIL 4, 2023

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive opinion on results from the CHAMPION-NMOSD Phase III trial. 1 In the CHAMPION-NMOSD trial , Ultomiris was compared to an external placebo arm from the pivotal Soliris PREVENT clinical trial.

Trials 40

Trials Medicine Antibody Clinical Trials 40

The Pharma Data

OCTOBER 29, 2020

Established ULTOMIRIS as new standard of care in PNH ahead of set goal, with more than 70% patient conversion from SOLIRIS ® (eculizumab) in 3 largest markets – U.S. The COVID-19 impact has varied by study and program, but there has been little timing impact on fully-enrolled trials. Received U.S. Germany & Japan.

Sales 40

Sales Clinical Trials Clinical Trials Production 40